Boston Scientific Launches Coyote(TM) Balloon Catheter
NATICK, Mass., Sept. 19, 2011 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) has launched its Coyote(TM) Balloon Catheter, a highly deliverable and ultra-low profile 0.014 inch balloon dilatation catheter designed to treat patients undergoing peripheral angioplasty procedures below the knee. The Company has begun marketing the product in the U.S., Europe and other international markets.
Boston Scientific developed the Coyote Balloon Catheter to help physicians better treat patients with challenging obstructive lesions in the lower extremities. It features an ultra-low lesion entry profile (0.017 inch), excellent crossing profile and a shaft optimized for outstanding deliverability. The balloon offers rapid deflation times and is available in lengths up to 220 mm on both Over-the-Wire (OTW) and MonorailÃ‚® platforms.
“The Coyote Balloon Catheter’s low profile and ability to navigate through challenging vasculature make it ideal for treating vessels in the lower extremities,” said J. A. Mustapha, M.D., Director of Endovascular Intervention at Metro Health Hospital in Wyoming, MI. “Its performance gives me greater confidence in being able to effectively treat patients with difficult anatomy who suffer from peripheral artery disease.”
“With an ultra-low profile and extended balloon lengths on a variety of catheter platforms, the Coyote Balloon Catheter is designed specifically for interventionalists treating patients with demanding peripheral lesions below the knee,” said Jeff Mirviss, President of Boston Scientific’s Peripheral Interventions Division. “It builds on Boston Scientific’s global leadership in low-profile peripheral balloon angioplasty and reflects our commitment to meeting physician and patient needs through innovative medical technology.”
Coyote is the latest in a series of innovative balloon catheter products introduced by Boston Scientific. In June, the Company launched its Mustang(TM) PTA Balloon Catheter, a highly deliverable 0.035 inch percutaneous transluminal angioplasty (PTA) catheter designed for a wide range of peripheral angioplasty procedures.
An estimated 8 to 10 million patients in the United States alone suffer from peripheral artery disease (PAD), which is characterized by blockages in vessels of the peripheral vasculature and associated with high rates of morbidity. Balloon catheters are used in peripheral angioplasty and stenting procedures to open blocked arteries.
To download a high-resolution image of the Coyote(TM) Balloon Catheter go to: http://bostonscientific.mediaroom.com/index.php?s=13&cat=16&mode=gallery.
About Boston Scientific
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend” and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding new product launches and launch cadence, regulatory approvals, the PAD market, product performance, our future business plans and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A — Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A — Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.
CONTACT: Erik Kopp 508-650-8660 (office) Media Relations Boston Scientific Corporation email@example.com Sean Wirtjes 508-652-5305 (office) Investor Relations Boston Scientific Corporation firstname.lastname@example.org
SOURCE Boston Scientific Corporation